Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View RLMD insider activity ↗

RLMDRELMADA THERAPEUTICS, INC.

THE LATEST REPORTED YEAR

The company reported a loss.

$57.39M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$5.13KYear ended August 31, 2013
Profit or loss-$57.39MYear ended December 31, 2025
Cash from the business-$45.79MYear ended December 31, 2025
Total assets$219.06MAs of June 30, 2026
Total liabilities$12.5MAs of June 30, 2026
Cash & equivalents$11.33MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$7.94K
2012-08
$5.13K
2013-08

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
September 1, 2012 – August 31, 2013$5,129December 16, 201310-K ↗
September 1, 2011 – August 31, 2012$7,941December 16, 201310-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 7, 2026

Response SHA-256: 34acb6579adb694402af1f940d83014f7841c8cf763b03e27ee64d386466bb53

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.